Effectiveness of Coenzyme Q10 and Glutathione in Preventing Acute Kidney Injury After Cardiac Surgery Using Cardiopulmonary Bypass

What this Trial Is About

Researchers are evaluating the effectiveness of mitochondrial-directed therapy to prevent acute kidney injury AKI associated with cardiac surgery involving cardiopulmonary bypass CPB. This trial focuses on adults undergoing elective CPB surgery who are at risk of AKI, a serious complication linked to increased mortality and long-term kidney disease. The study explores the role of mitochondrial dysfunction in AKI development and tests therapies aimed at protecting kidney function during surgery. Participants will be randomly assigned to receive either a combination of Coenzyme Q10 CoQ10 at 1200 mg daily and Glutathione GSH at 1000 mg daily, or matching placebos. The first dose is given the day before surgery and continued daily while admitted, for up to one week. CoQ10 and Glutathione are supplements thought to protect mitochondria and reduce oxidative stress. The placebo capsules are designed to look identical to the active treatments. During the study, blood and urine samples will be collected to monitor kidney function and any side effects. Researchers will track the incidence of AKI up to 28 and 90 days after surgery to assess treatment impact. Safety is monitored by recording any adverse events related to the study drugs. The trial involves regular assessments while admitted and follow-up to evaluate kidney outcomes over several months.

Prevent Cardiac Surgery Associated AKI Trial